Novel Bi-Specific Antibody Therapy to Treat Relapsed ALL: Blinatumomab in Action

Track: Pediatric BMT Program
Thursday, February 27, 2014, 3:00 PM-4:30 PM
Grapevine C (Gaylord Texan)
Lia Gore, MD , Pediatrics and Medical Oncology, Children's Hospital Colorado and University of Colorado, Aurora, CO
Disclosures:
L. Gore, Amgen , Advisory Board Member: Advisory Board and Travel expenses for DSMC meeting paid by sponsor
Onyx, Advisory Board Member: Advisory Board and Travel expenses paid by sponsor to attend Ad Board meeting
Celgene, DSMC Member: DSMC member; unpaid
MedImmune, DSMC Chair: DSMC chair
Epizyme, Advisory Board member: Advisory Board
See more of: (PEDS) Relapse after BMT
See more of: Pediatric BMT Program
<< Previous Presentation | Next Presentation